AI Article Synopsis
- - The study examines the effectiveness of combining intensity-modulated radiotherapy (IMRT) with Gamma Knife Radiosurgery (GKRS) for treating locally advanced head and neck cancer, focusing on cases close to sensitive structures.
- - A review of 20 patients treated between 2011 and 2021 showed a high local control rate of 95% and a 2-year overall survival rate of 94.7%, with only a few cases of progression.
- - The combination treatment presented effective disease management with low toxicity, although some patients experienced brain radionecrosis, indicating a need for careful monitoring.
Article Abstract
Background: To describe intensity-modulated radiotherapy (IMRT) with Gamma Knife Radiosurgery (GKRS) boost for locally advanced head and neck cancer (HNC) with disease near dose-limiting structures.
Methods: Patients with HNC treated with IMRT/GKRS as part of a combined modality approach between 2011 and 2021 were reviewed. Local control, overall survival and disease-specific survival were estimated using the Kaplan Meier method.
Results: Twenty patients were included. Nineteen patients had T3-4 tumors. Median follow-up was 26.3 months. GKRS site control was 95%. Two patients progressed at the treated primary site, one patient failed at the edge of the GKRS treatment volume, with no perineural or intracranial failure. 2-year OS was 94.7% (95% CI: 85.2%-100%). Concurrent chemotherapy was given in nine patients (45%). One patient (5%) received induction/concurrent chemotherapy. Brain radionecrosis occurred in three patients, one of which was biopsy-proven.
Conclusions: IMRT plus GKRS boost results in excellent disease control near critical structures with minimal toxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813854 | PMC |
| http://dx.doi.org/10.1002/hed.27176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective Observational Study on Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer in Rwanda: Acute Toxicity in Patients.
JCO Glob Oncol
December 2024
Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Purpose: Moderate hypofractionation (MHF) offers logistical and financial advantages, and has become standard in Western countries but not yet in Africa. This study assessed GI and genitourinary (GU) acute toxicity in Rwandan men undergoing MHF (20 × 3 Gy) treatment.
Materials And Methods: Since 2021, patients with prostate cancer at the Rwanda Cancer Centre have been informed about the study on MHF treatment and could participate by signing an informed consent.
Hypoxia-guided treatment planning for lung cancer with dose painting by numbers.
J Appl Clin Med Phys
December 2024
Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Tumor hypoxia significantly impacts the efficacy of radiotherapy. Recent developments in the technique of dose painting by numbers (DPBN) promise to improve the tumor control probability (TCP) in conventional radiotherapy for hypoxic cancer. The study initially combined the DPBN method with hypoxia-guided dose distribution optimization to overcome hypoxia for lung cancers and evaluated the effectiveness and appropriateness for clinical use of the DPBN plans.
View Article and Find Full Text PDFTreating early-stage centrally-located non-small cell lung cancer with DCAT-SBRT in centers lacking the VMAT technique: a comprehensive study.
Front Oncol
December 2024
School of Nuclear Science and Engineering, East China University of Technology, Nanchang, Jiangxi, China.
Background: Volumetric-modulated arc therapy (VMAT) may have the highest overall performance for stereotactic body radiotherapy (SBRT) treatment of inoperable early-stage NSCLC. However, in centers lacking the VMAT technique, the dynamic conformal arc therapy (DCAT) technique is potentially the best option for small and rounded NSCLC-SBRT. Therefore, we will comprehensively analyze the advantages of the DCAT versus the other techniques except VMAT in terms of dosimetry, plan complexity, delivery time, γ-passing rates and the interplay effect.
View Article and Find Full Text PDFLong-term Outcomes Following Individualized Elective Primary Tumor CTV Delineation Based on Stepwise Spread Patterns of Nasopharyngeal Carcinoma Treated with Intensity-modulated Radiotherapy.
Int J Radiat Oncol Biol Phys
December 2024
Department of Radiation Oncology, Sun Yat-sen University Cancer Center; Collaborative Innovation Center for Cancer Medicine; State Key Laboratory of Oncology in South China;Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy;Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, P.R. China. Electronic address:
Purpose: Our institution has developed an individualized elective primary tumor clinical target volume (CTVp) delineation protocol for nasopharyngeal carcinoma (NPC) based on stepwise tumor spread patterns in intensity-modulated radiotherapy (IMRT) for over ten years. Herein, we report the long-term efficacy and toxicities in NPC patients treated under this protocol.
Methods And Materials: A total of 7,262 histologically proven, nonmetastatic NPC patients treated with IMRT following this individualized delineation protocol were retrospectively evaluated.
Efficacy and Failure Patterns Following Target Volume and Dose Reduction After Neoadjuvant Therapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Head Neck
December 2024
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Background: In this study, we aimed to analyze the efficacy and failure patterns of contouring target volume based on the residual tumor and decreasing the dose to the area of tumor regression after neoadjuvant therapy in locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
Methods: We retrospectively analyzed the patients with locoregionally advanced HNSCC treated by our group from May 2011 to June 2023. All patients received neoadjuvant therapy followed by intensity-modulated radiation therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!